1. Home
  2. MTVA vs SKK Comparison

MTVA vs SKK Comparison

Compare MTVA & SKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTVA
  • SKK
  • Stock Information
  • Founded
  • MTVA 2014
  • SKK 2013
  • Country
  • MTVA United States
  • SKK Singapore
  • Employees
  • MTVA N/A
  • SKK N/A
  • Industry
  • MTVA
  • SKK
  • Sector
  • MTVA
  • SKK
  • Exchange
  • MTVA NYSE
  • SKK NYSE
  • Market Cap
  • MTVA 14.3M
  • SKK 11.6M
  • IPO Year
  • MTVA N/A
  • SKK 2024
  • Fundamental
  • Price
  • MTVA $0.66
  • SKK $0.65
  • Analyst Decision
  • MTVA Strong Buy
  • SKK
  • Analyst Count
  • MTVA 2
  • SKK 0
  • Target Price
  • MTVA $7.50
  • SKK N/A
  • AVG Volume (30 Days)
  • MTVA 133.9K
  • SKK 121.6K
  • Earning Date
  • MTVA 08-13-2025
  • SKK 02-14-2025
  • Dividend Yield
  • MTVA N/A
  • SKK N/A
  • EPS Growth
  • MTVA N/A
  • SKK 99.13
  • EPS
  • MTVA N/A
  • SKK 0.03
  • Revenue
  • MTVA N/A
  • SKK $11,301,000.00
  • Revenue This Year
  • MTVA N/A
  • SKK N/A
  • Revenue Next Year
  • MTVA N/A
  • SKK N/A
  • P/E Ratio
  • MTVA N/A
  • SKK $24.63
  • Revenue Growth
  • MTVA N/A
  • SKK 15.80
  • 52 Week Low
  • MTVA $0.63
  • SKK $0.53
  • 52 Week High
  • MTVA $5.30
  • SKK $11.45
  • Technical
  • Relative Strength Index (RSI)
  • MTVA N/A
  • SKK N/A
  • Support Level
  • MTVA N/A
  • SKK N/A
  • Resistance Level
  • MTVA N/A
  • SKK N/A
  • Average True Range (ATR)
  • MTVA 0.00
  • SKK 0.00
  • MACD
  • MTVA 0.00
  • SKK 0.00
  • Stochastic Oscillator
  • MTVA 0.00
  • SKK 0.00

About MTVA METAVIA INC

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

About SKK SKK HOLDINGS LIMITED

SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.

Share on Social Networks: